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Introduction: Inflammatory breast cancer (IBC) is an aggressive type of breast cancer, characterized by very rapid
progression, enlargement of the breast, skin edema causing an orange peel appearance (peau d’orange), erythema,
thickening, and dermal lymphatic invasion. It is characterized by E-cadherin overexpression in the primary and
metastatic disease, but to date no robust molecular features that specifically identify IBC have been reported.
Further, models that recapitulate all of these clinical findings are limited and as a result no studies have
demonstrated modulation of these clinical features as opposed to simply tumor cell growth.
Methods: Hypothesizing the clinical presentation of IBC may be mediated in part by the microenvironment, we
examined the effect of co-injection of IBC xenografts with mesenchymal stem/stromal cells (MSCs).
Results: MSCs co-injection significantly increased the clinical features of skin invasion and metastasis in the SUM149
xenograft model. Primary tumors co-injected with MSCs expressed higher phospho-epidermal growth factor receptor
(p-EGFR) and promoted metastasis development after tumor resection, effects that were abrogated by treatment with
the epidermal growth factor receptor (EGFR) inhibitor, erlotinib. E-cadherin expression was maintained in primary tumor
xenografts with MSCs co-injection compared to control and erlotinib treatment dramatically decreased this expression
in control and MSCs co-injected tumors. Tumor samples from patients demonstrate correlation between stromal and
tumor p-EGFR staining only in IBC tumors.
Conclusions: Our findings demonstrate that the IBC clinical phenotype is promoted by signaling from the
microenvironment perhaps in addition to tumor cell drivers.Introduction
Inflammatory breast cancer (IBC) is an aggressive type of
breast cancer, characterized by rapid progression, enlarge-
ment of the breast, skin edema resulting in a peau d’or-
ange appearance, erythema, thickening, and dermal
lymphatic invasion. IBC is often misdiagnosed and has a
worse prognosis than non-IBC because of the high inci-
dence of distant metastasis at diagnosis [1,2]. While genes* Correspondence: wwoodward@mdanderson.org
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unless otherwise stated.and molecular features that are enriched in IBC have been
identified, to date, few molecular features have been iden-
tified that uniquely and specifically distinguish IBC from
other types of breast cancer. In fact, one such described
gene expression signature trained and validated in IBC
samples [3] classifies 25% of samples in the public The
Cancer Genome Atlas (TCGA) database as ‘IBC-like’ [4].
At this time, the basis of the diagnosis of IBC remains
clinical features, including time to progression and extent
of symptoms. In the absence of clear evidence that IBC
tumor cells are completely distinct from non-IBC tumor
cells, we sought to investigate the role of the microenvir-
onment in mediating the IBC phenotype.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tent progenitor cells found in normal tissues that have a
unique tropism for tumors where they engraft, form
tumor stroma, and alter the tumor microenvironment.
MSCs have also been shown to increase the growth of
certain cancers and the incidence of metastasis in breast
xenograft models [5,6]. We recently reported that condi-
tioned medium collected from MSCs cultured as spheres
increased the ability of the IBC cell lines SUM149 and
MDA-IBC3 to form mammospheres, and co-injection of
MSCs with MDA-IBC3 cells shortened the latency
period for tumor formation [7]. In addition, MSCs and
their conditioned medium decreased the expression of
E-cadherin and increased the expression of other
epithelial-to-mesenchymal transition (EMT)-related pro-
teins like N-cadherin, vimentin, and fibronectin [7].
Therefore, we hypothesized that the presence of MSCs
and their secreted factors in the microenvironment
increase EMT and cancer stem cell populations in IBC.
Indeed several translational studies have suggested that
IBC is enriched in cancer stem cells (reviewed in [8]).
To formally test our hypothesis, we used an in vivo
xenograft model to investigate the tumor-initiating abil-
ity of cells cultured as mammospheres in the presence of
MSC-conditioned medium (MSC-CM) and cells co-
injected with MSCs. We unexpectedly found xenograft
skin invasion, the clinical sine qua non of IBC that is not
reproducibly observed in all IBC xenograft models, was
induced by MSCs and MSC-CM. Metastasis was in-
duced as well, but paradoxically MSC-CM reduced
tumor initiation rather than increasing it.
Several studies have shown that the epidermal growth
factor receptor (EGFR), which is overexpressed in 30%
of IBC cases, is an independent predictor of poor prog-
nosis in IBC and is associated with poor overall survival
and high risk of recurrence in patients with IBC [9,10].
Furthermore, it has been reported that EGFR and EGFR
phosphorylation promotes proliferation and invasion of
IBC cells and is a relevant target in IBC [11,12], and that
epidermal growth factor (EGF) secretion by the micro-
environment’s tumor-associated macrophages is neces-
sary to activate the invasive and metastatic potential of
mammary epithelial cells [13]. Therefore, we further in-
vestigated MSC-IBC interactions by inhibiting EGFR
with erlotinib and found that erlotinib reduced MSC-
promoted metastasis and downregulated E-cadherin ex-
pression in primary tumors. In summary, we found that
MSCs promote the IBC skin phenotype and metastasis
independent of tumor initiation and that EGFR inhib-
ition blocks MSC-promoted metastasis in IBC. Our
findings show the value of including MSCs in human
xenograft preclinical models to better recapitulate the
clinical phenotype of IBC, and they support the concept




The IBC cell line SUM149 was obtained from Asterand
(Detroit, MI, USA) and cultured in Ham’s F-12 media
supplemented with 10% fetal bovine serum (FBS), 1 mg/
mL hydrocortisone, 5 mg/mL insulin, and 1% antibiotic-
antimycotic. Human-derived bone marrow MSCs were
obtained from EMD Millipore (Billerica, MA, USA)
(Part #SCC034, Lot N61710996) and cultured in alpha
minimum essential medium (MEM) supplemented with
20% FBS and 1% penicillin/streptomycin/glutamine.
Lentiviral production and transduction
The lentiviral vectors pFULG and pFULT (kindly provided
by Dr. Jennifer Prescher, UC-Irvine) encode the firefly lucif-
erase 2-eGFP and firefly luciferase 2-Tomato red dual-
reporter proteins, respectively [14]. To produce high-titer
lentivirus, about 1.2 × 107 293 T cells were plated in 15-cm
cell culture dishes in 25 mL Dulbecco’s MEM supple-
mented with 10% FBS. The next day, cells were transfected
with Fugene 6 (Promega, Madison, WI, USA) DNA mix-
ture (12 μg of pFULG or pFULT vector, 4 μg of pRSV-Rev,
4 μg of pMDLg-pRRE, and 4 μg of pCMV-VSVG) and were
incubated overnight. The culture medium was then re-
moved and replaced with fresh medium. The supernatant
containing the virus was then collected, filtered through a
0.45-μm HV Durapore membrane (EMD Millipore) to
remove cells and large debris, and concentrated by ultra-
centrifugation. For transduction, 60% to 70% confluent
SUM149 cell cultures were used. Two hours before trans-
duction, the medium was changed, and then transductions
were carried out for 24 h in the presence of 8 μg/mL poly-
brene (Sigma-Aldrich, St Louis, MO, USA). Finally, cells
expressing green fluorescent protein (GFP) and Tomato
red protein were sorted twice by fluorescence-activated
cell sorting and expanded before in vitro and in vivo
experiments.
Culture of mammospheres
To generate mammospheres from SUM149 cells, 2 × 104
cells/mL were cultured in serum-free MEM supplemented
with 20 ng/mL basic fibroblast growth factor, 20 ng/mL
EGF, and B27 (all from Invitrogen, Carlsbad, CA, USA) in
ultra-low attachment plates [15-17].
Preparation of MSC-CM
MSC spheroids were obtained by plating MSCs at 2 × 104
cells/mL in ultra-low attachment plates and culturing them
in serum-free growth factor-enriched medium as described
above. After 5 days of culture, spheres were removed by
centrifugation and supernatant was filtered through a 0.2-
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immediately or stored at −80°C until needed.
Injection of SUM149 cells pretreated with MSC-CM in vitro
SUM149 cells labeled with dual-luciferase-Tomato red re-
porter gene (pFULT) vector were cultured in vitro as mam-
mospheres with or without MSC-CM (50% total volume)
for 5 days before being trypsinized and injected into the #4
(left side) cleared mammary fat pad of female immunocom-
promised SCID/Beige mice (3 to 5 weeks old) at one of two
dilutions: 1 × 105 and 2 × 104 cells per injection. Trans-
plants were allowed to grow until the tumors reached
300 mm3 (monitored with caliper measurements) and were
then resected in a survival surgery.
Co-injection of SUM149 cells with MSC
SUM149 cells were injected into the #4 and #9 cleared
mammary fat pads of female immunocompromised SCID/
Beige mice (3 to 5 weeks old), with or without 10% MSCs,
in a total of 5 × 105 cells per injection. SUM149 were
injected in both sides of each mouse. Cells injected into
the #4 (left side) mammary fat pad of mice were labeled
with dual-luciferase-Tomato red reporter gene (pFULT)
vector and cells injected into the #9 (right side) mammary
fat pad of mice were labeled with dual luciferase-GFP re-
porter gene (pFULG) vector. For co-injections, 5 × 104
MSCs were premixed with SUM149 cells and the mixture
co-injected in the #4 (left side) mammary fat pad of the
mice in the 10% MSC group (see Scheme 1). Transplants
were allowed to grow to 300 mm3 (monitored with caliper
measurements) and were then resected in a survival
surgery.
Follow-up of tumor-skin involvement and metastasis
development
Tumor-skin involvement was accessed visually during pri-
mary tumor growth (loss of fur at tumor site, redness and
thickness of skin), during tumor excision (tumors firmly
connected with skin) and after tumor resection (loss of
fur, redness, and thickness of skin at any site). The devel-
opment and localization of metastasis was monitored by
bioimaging the luciferase signal (IVIS Spectrum systemScheme 1 Bilateral injections plan. Mice on control and erlotinib diets w
were co-injected in one side (left) with 10% mesenchymal stem cells (MSC(Caliper Life Sciences, Hopkinton, MA, USA)). Findings
between groups were compared with Fisher’s exact test.
Histology
Necropsy was performed for all mice, and metastases and
major organs (lung, spleen, and liver) were collected.
Formalin-fixed, paraffin-embedded sections of primary
tumors and metastatic sites were stained with hematoxylin
and eosin (H&E) and used for immunohistochemical stain-
ing to detect markers such as Ki-67 (tumor proliferation),
caspase 3 (apoptosis), E-cadherin (adhesion), F4/80 (macro-
phages), aldehyde dehydrogenase (ALDH, a marker of
tumor-initiating cells) and p-EGFR (tumor signaling). All
staining was done by the core lab at MD Anderson Cancer
Center with standard, validated protocols and the findings
were analyzed by a pathologist specializing in IBC (SK).
In vivo treatment with erlotinib, an EGFR tyrosine kinase
inhibitor
After SUM149 cells with or without 10% MSCs had
been injected into the cleared mammary fat pads of
female immunocompromised SCID/Beige mice as de-
scribed above, mice were fed a diet including erlotinib
(a dose of 40 mg/kg per day), started on day 1 following
injection of cells and continued for 17 weeks.
Statement of ethical approval
All mice used in the work here described were housed
and used in accordance with institutional guidelines of
The University of Texas MD Anderson Cancer Center
under protocols 07-08-07232 and 07-08-07132, ethically
approved by the MD Anderson Cancer Center Institu-
tional Animal Care and Use Committee (IACUC). MD
Anderson Cancer Center’s animal care and use program
has been fully accredited by the Association for the As-
sessment and Accreditation of Laboratory Animal Care
International (AAALAC).
Patient samples
A tumor tissue microarray (TMA) was created with primary
tumor samples acquired from breast cancer patients with
written informed consent and experimental procedures wereere injected bilaterally with SUM149 cells, but only half of the mice
s).
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Anderson Cancer Center Institutional Review Board. Details
about the preparation of the TMA can be found elsewhere
[18]. The TMA was stained for phospho-epidermal growth
factor receptor (p-EGFR) at the core lab at MD Anderson
Cancer Center with standard, validated protocols. The stain-
ing results were evaluated by an experienced pathologist
(YG) for the percentage of positive cells and intensity of
staining in both tumor cells and stromal cells.
Statistical analysis
All data are represented in graphs as means ± standard
error of the mean (SEM). Statistical analyses were per-
formed with GraphPad Prism version 6 (Graphpad Soft-
ware, San Diego, CA, USA). A P value of 0.05 in paired
two-sided Student’s t tests, log-rank tests, or Fisher’s exact
tests was considered statistically significant. Chi-square
tests were used to analyze results of the limiting dilution
experiment by using the extreme limiting dilution analysis
(ELDA) web tool [19]. Correlation of tumor and stromal in-
tensity staining was evaluated using the Mantel-Haenszel
tests for trend. Distant metastasis-free survival was exam-
ined using Kaplan-Meier plots and the log-rank tests in
SPSS version 11 (SPSS Inc., Chicago, IL, USA).
Results
Pretreatment with MSC-CM reduced tumor initiation but
promoted skin invasion in IBC xenografts
We previously reported that MSC-CM increased primary
mammosphere formation (but not secondary mammo-
sphere formation) and protein expression consistent with
EMT from IBC cell lines. While this is consistent with the
known association between MSC and metastases, the ab-
sence of effect on secondary mammospheres suggests,
somewhat unexpectedly, that this is not a self-renewing
phenomenon. To specifically test the correlation between
primary mammosphere formation and tumor initiation, we
investigated the effects of MSC-CM on in vivo tumor initi-
ation. Triple-negative IBC SUM149 cells were cultured as
mammospheres in the presence of 50% (total volume)
MSC-CM for 5 days. After this in vitro pretreatment, we
dissociated mammospheres into single cells and injected
conditioned cells or control cells into the cleared mammary
fat pads of SCID/Beige mice (20 mice per group, four
groups). No differences were found in the cell cycle and
apoptosis of cells pretreated with or without MSC-CM (see
Figure S1 in Additional file 1). We used two cell dilutions: a
permissive cell dilution (injection of 1 × 105 conditioned ver-
sus control cells, in anticipation of 75% tumor formation in
the control condition), and a restrictive cell dilution (2 × 104
conditioned versus control cells, in anticipation of 50%
tumor formation in the control), based on findings reported
by Fillmore et al. [16]. Tumor initiation was monitored for
up to 6 months. We observed that SUM149 cells that hadbeen pretreated with MSC-CM formed significantly fewer
tumors than did control cells (P= 0.04, ELDA; Figure 1A)
suggesting MSC-CM decreased tumor-initiating cells in this
IBC cell line. In addition, comparing groups of tumors ob-
tained with 1 × 105 cells, those obtained from SUM149 cells
that had been pretreated with MSC-CM showed significant
growth delay than control tumors, taking a longer time to
be palpable after cell injection, as can be seen in Figure 1B
(112.0 days vs. 55.0 days, P = 0.001, log-rank test); and grew
more slowly than control tumors, taking more time to reach
the required volume (300 mm3) for tumor resection, as can
be seen in Figure 1C (102.3 days vs. 50.0 days, P= 0.001,
Student’s t test).
All tumors were allowed to grow up to 300 mm3 and
were then resected in a survival surgery and skin inva-
sion was examined. Interestingly, in the group injected
with SUM149 cells pretreated with MSC-CM, 9 of 13 tu-
mors were invading the skin, whereas in the control
group only 4 of 16 tumors had displayed skin invasion
(P = 0.03, Fisher’s exact test; Figure 1D). A representative
image of gross skin involvement concomitant with the
development of metastasis in the axilla, resembling the
IBC clinical phenotype of skin invasion, thickening,
edema and erythema that can spread via the lymphovas-
cular system beyond the clinical breast mound is
depicted in Figure 1 (images E and F). Notably, dermal
lymphovascular invasion, a characteristic of IBC not uni-
formly present in cell-line derived xenografts from IBC
cell lines, was confirmed histologically (Figure 1G
and H). This is noteworthy because the failure of most
IBC cell-based xenografts to faithfully recapitulate the
clinical features that define the disease is a significant
limitation for identifying clinically relevant targets. Our
results show that MSC-CM decreased the tumor initi-
ation of SUM149 cells, suggesting that fewer tumor-
initiating cells were present after in vitro exposure to
MSC-CM. Nevertheless, pretreatment with MSC-CM
promoted tumor skin invasion and IBC clinical pheno-
type after primary tumor resection from the tumors that
do form, implying that factors secreted by MSCs may
change a subpopulation of IBC cells to a phenotype that
is more able to recapitulate the IBC clinical phenotype
in a preclinical rodent model.
MSCs inhibited primary tumor growth but increased skin
invasion and development of metastases
The tumor initiation experiment was not powered for
comparing metastasis between the two arms, and the
finding of increased skin invasion was unexpected. To
validate the findings described above and to determine if
secreted factors from MSCs or direct contact between
MSCs and cancer cells further modifies the invasive
characteristics of IBC cells in vivo including metastasis
formation, we examined the ability of bilaterally injected
Figure 1 (See legend on next page.)
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Figure 1 Pretreatment with conditioned medium from mesenchymal stem/stromal cells (MSC-CM) reduces tumor initiation and delays tumor
growth but promotes skin invasion in an inflammatory breast cancer (IBC) xenograft model. SUM149 cells were cultured in vitro as mammospheres
with and without MSC-CM for 5 days and then injected into the cleared mammary fat pad of SCID/Beige mice at two different dilutions: 1 × 105 and 2× 104
(20 mice per group). Tumor initiation was monitored for 6 months. (A) Number of tumors observed in each group of injections. Tumor initiation of SUM149
cells following pretreatment with MSC-CM at permissive and restrictive cell dilutions is lower than control SUM149 cells. P= 0.04; ELDA. (B) Time to tumor
initiation (palpable tumor). Blue line, control 1 × 105 cells; gold line, MSC-CM 1× 105 cells; green line, control 2 × 104 cells; red line, MSC-CM 2× 104 cells.
***P= 0.001, log-rank test. Tumor latency of SUM149 cells following pretreatment with MSC-CM (gold line) at a permissive cell dilution is longer than control
SUM149 cells (blue line). (C) Time to tumor development between palpable and a volume of 300 mm3. Tumor growth of SUM149 cells following
pretreatment with MSC-CM at a permissive cell dilution is slower comparing with control SUM149 cells. ***P = 0.001, Student’s t test. (D) Number of
tumors that showed skin invasion in groups injected with 1 × 105 SUM149 cells. Tumors of SUM149 cells pretreated with MSC-CM invaded the skin
of mice more frequently than control SUM149 cells. *P = 0.03, Fisher’s exact test. (E) Image of a mouse injected with SUM149 cells pretreated with
MSC-CM showing gross skin involvement following primary tumor resection. (F) Image of same mouse as in E showing metastasis in the axilla by
bioimaging of luciferase signal. (G and H) Hematoxylin and eosin (H&E) staining of tissue section from a mouse injected with 1 × 105 SUM149 cells
pretreated with MSC-CM showing IBC characteristic dermal lymphovascular invasion (dermolymphatic tumor emboli). Scale bar is 200 μm in
all images.
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metastasize when MSCs had been added to the tumor
microenvironment on one side. For this purpose, cell
suspensions of SUM149 cells and human bone marrow-
derived MSCs were prepared from monolayer cultures
(60% to 80% confluence). In the control group (0%
MSC), SUM149 cells were bilaterally injected into #4
and #9 mammary cleared fat pads of SCID/Beige mice,
and in the experimental group (10% MSC), SUM149 and
MSCs were mixed and then co-injected into #4 (left)
mammary cleared fat pad, and SUM149 only were
injected into the #9 (right) mammary gland. Hereafter,
tumors with SUM149 cells co-injected with MSCs are
referred to as ipsilateral, and the tumor in the same
mouse without MSCs is referred to as contralateral
(Scheme 1). Interestingly, the control mice with no MSC
co-injection demonstrated an obvious difference in
growth between sides, with the left-sided tumors grow-
ing significantly faster. A bilateral tumor model was
chosen to allow examination of circulation of tumor
cells from one tumor to the other. As described in the
Methods, the labeling vectors were distinct in the left-
versus right-sided tumors in the control and experimen-
tal mice, but no gross differences were noted in the
growth of cells with the different labeling vectors
in vitro. (Interestingly, Robichaux et al. reported vari-
ation in gene expression in left versus right normal
mammary gland [20]). For this reason, results are pre-
sented as both the average tumor burden per mouse in
each group and left- and right-sided tumors of the con-
trol group versus the respective left- and right-sided
experimental group. Monitoring tumor growth we ob-
served that although tumor latency was significantly shorter
for 10% MSC mice (24.5 days vs. 32.5 days, P = 0.002, Stu-
dent’s t test; Figure 2A), as in the MSC-CM experiment the
tumors in this group once formed reached 300 mm3 much
more slowly than tumors in the control group (55.1 days
vs. 41.0 days, P = 0.001, Student’s t test; Figure 2B). There-
fore, co-injection of MSCs promoted faster initiation ofslower-growing tumors. Examining tumor growth delay
(average of tumor burden per mouse) also showed that co-
injection of MSC delayed the growth of SUM149 tumors
(P = 0.02, Student’s t test; Figure 2C). Examination of the
tumor growth delay by laterality revealed this difference
was entirely accounted for by inhibition of the contralateral
tumors in mice co-injected with MSCs. That is, co-
injection of MSCs did not change the growth of tumors
where the MSC were actually present (left side), but instead
MSCs inhibited the growth of their respective contralateral
tumors (right side) (Figure 2D). No histologic differences
were noted among tumors from different groups and im-
plantation position, as assessed by staining and examination
of tissue sections of primary tumors with H&E. All tumors
were very poorly differentiated and high grade (Figure 2E
to H).
Survival surgeries were again performed and skin inva-
sion examined. The 10% MSC group had significantly
more mice with tumor-skin invasion than the control
group (11 of 18 vs. 4 of 20, P = 0.02, Fisher’s exact test;
Figure 2I). This effect was not limited to the co-injected
side. Subsequently, we monitored the development of
metastasis by using live bioimaging to detect luciferase
signal. Within 8 weeks, mice developed spontaneous
metastasis. Mice co-injected with 10% MSC had signifi-
cantly more spontaneous metastasis after resection than
control (12 of 17 vs. 7 of 19, P = 0.05, Fisher’s exact test),
and 30-day actuarial metastasis-free survival rates calcu-
lated from the day of resection were 74% for the 0%
MSC group versus 47% for the 10% MSC group (P =
0.05, log-rank test; Figure 2J). Our results show that
MSCs delayed the growth of SUM149 contralateral tu-
mors, suggesting that MSCs secrete inhibitory factors
that change and effect tumor growth in locations other
than the site where MSCs are present. On the other
hand, MSCs and their factors promote tumor-skin inva-
sion and spontaneous metastasis in this preclinical
model of IBC that otherwise has a low rate of spontan-
eous metastasis.
Figure 2 (See legend on next page.)
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Figure 2 Mesenchymal stem/stromal cells (MSCs) inhibit primary tumor growth but increase skin invasion and development of
metastasis. SUM149 cells (5 × 105) were injected bilaterally into the cleared mammary fat pad of SCID/Beige mice with or without MSCs (10% of
total number of cells injected per mammary gland, see Scheme 1). Tumor growth and tumor-skin involvement were monitored and tumors were
resected in a survival surgery when tumors reached a volume of 300 mm3. Development of metastases was monitored for 8 weeks post-resection
of primary tumor. (A) Time for tumor first detection by palpation. Tumor latency of mice co-injected with 10% MSC is shorter than control group
(0% MSC). **P = 0.002, Student’s t test. (B) Time to tumor development between palpable and a volume of 300 mm3. Tumor growth of mice
co-injected with 10% MSC is slower than control group (0% MSC). ***P = 0.001, Student’s t test. (C) Tumor growth curves of 0% and 10% MSC
groups prepared with average of tumor burden per mouse, showing a statistical difference between groups. *P = 0.02, Student’s t test. (D) Tumor
growth curves of 0% and 10% MSC groups prepared with average of tumor volume per side of injection, showing inhibition of contralateral
tumors via co-injection of 10% MSC. (E) Hematoxylin and eosin (H&E) staining of tumor section of left-sided tumor from 0% MSC group. (F) H&E
staining of tumor section of right-sided tumor from 0% MSC group. (G) H&E staining of tumor section of left-sided (ipsilateral) tumor from 10%
MSC group. (H) H&E staining of tumor section of right-sided (contralateral) tumor from 10% MSC group. Scale bar is 100 μm in all images. (I)
Number of tumors that showed skin invasion. Tumors of SUM149 cells co-injected with 10% MSC invaded the skin of mouse more frequently
than control SUM149 cells (0% MSC). *P = 0.02, Fisher’s exact test. (J) Metastasis-free survival curve. Blue line, 0% MSC; green line, 10% MSC.
P = 0.05, log-rank test. Mice co-injected with 10% MSC developed more rapidly spontaneous metastasis after resection than control group.
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green fluorescent report vectors for left and right injec-
tions, after tumor resection only a minority of tumor
cells demonstrated fluorescent signal by flow cytometry,
limiting the use of these data. Differences in label reten-
tion may be a factor in baseline laterality differences al-
though the low percentage of labeled cells in tumors
may also reflect stromal content. Nevertheless, flow cy-
tometry revealed no transfer of tumor cells between bi-
lateral tumors in mice with or without MSC co-injection
(see Figure S2A and B in Additional file 2), and metasta-
ses were demonstrated from both red and green tumor
cells by fluorescent bioimaging after lung collection (n =
2, see Figure S2C-F in Additional file 2). MSC are ex-
pected to stop proliferating and to get infinitely diluted
within the tumor cells, therefore we did not attempt to
track these cells.Co-injection of MSCs increased tumor proliferation and
EGFR signaling and increased the sensitivity of metastatic
IBC xenografts to erlotinib
Immunostaining for markers of tumor proliferation (Ki-
67), apoptosis (caspase-3), tumor-initiating cells (ALDH),
macrophage infiltration (F4/80), E-cadherin, and EGFR
signaling (phospho-EGFR, p-EGFR) were compared be-
tween control and 10% MSC primary tumors. E-cadherin
staining was similar between the 0% and 10% MSC groups
(P =NS, Student’s t test; Figure 3A-C). However, tumors
from the 10% MSC group had increased Ki-67 (P <0.001,
Student’s t test; Figure 3D-F) and p-EGFR (P = 0.045, Stu-
dent’s t test; Figure 3G-I) staining relative to the 0% MSC
group. No differences were found in caspase-3, ALDH, or
F4/80 staining (see Figure S3 in Additional file 3). Our re-
sults show that MSCs increase the proliferation of
SUM149 primary tumors (which did not translate into lar-
ger primary tumors) and that these tumors have activated
EGFR signaling. Immunostaining tissue sections of the
metastasis obtained after primary tumor resection for Ki-67, E-cadherin, p-EGFR, and F4/80 revealed no differences
between the 0% and 10% MSC groups (data not shown).
To examine the effects of EGFR signaling blockade on
MSC-induced metastases and skin invasion, control and
MSC co-injected mice were treated with erlotinib
(40 mg/kg), starting on the day after injection of cells
(SUM149 with or without MSCs). Of note, erlotinib
treatment of established tumors independent of MSC
has been shown previously to be effective in SUM149
xenografts at daily dosages between 50 and 100 mg/kg
in athymic nu/nu mice for 28 days [11]. Erlotinib treat-
ment in SCID/Beige mice (40 mg/kg) was associated
with significant toxicity, including weight loss (see
Figure S4A in Additional file 4), fur loss, and death (3
mice of 0% MSC group and 9 mice of 10% MSC group
died during erlotinib treatment). Nevertheless, erlotinib
delayed tumor growth for approximately 8 weeks in the
mice co-injected with SUM149 cells and MSCs and in
control mice compared with the mice whose diet did
not contain erlotinib (Figure 4A and B). However
8 weeks after injection, while mice were still receiving
the drug, tumors were detected by palpation in the mice
on the erlotinib diet, suggesting the development of re-
sistance (Figure 4C). Erlotinib treatment was stopped at
17 weeks to allow the mice to recover from the drug-
induced toxicity before undergoing the tumor-resection
survival surgery. Comparing arms in the interval after
development of tumor but before the removal of drug,
we observed that unlike the no erlotinib treatment
groups described earlier, MSC ipsilateral tumors in mice
treated with erlotinib were significantly suppressed
compared to the relevant control, suggesting that the
upregulation of p-EGFR signaling by MSCs made these
tumors more sensitive to erlotinib (Figure 4D and E)
without affecting tumor histology (see Figure S4B-E in
Additional file 4). The effect of the drug on the mice’s
body weight was not fully controlled; therefore weight
loss may have played a role in the observed slower
tumor growth, however, differences between groups
Figure 3 Tumor proliferation and epidermal growth factor receptor (EGFR) signaling are increased in mice co-injected with SUM149 cells and
mesenchymal stem/stromal cells (MSCs). SUM149 cells (5 × 105) were injected bilaterally into the cleared mammary fat pad of SCID/Beige mice with or
without MSCs (10% of total number of cells injected per mammary gland). Tumors were resected in a survival surgery when tumors reached a volume of
300 mm3, fixed in formalin, embedded in paraffin, cut, stained and scored by a pathologist specialized in inflammatory breast cancer (IBC). (A) E-cadherin
staining of tumor section from 0% MSC group. (B) E-cadherin staining of tumor section from 10% MSC group. (C) Quantification and comparison of
E-cadherin staining between 0% and 10% MSC groups. E-cadherin staining was similar between 0% and 10% groups. P=NS, Student’s t test. (D) Ki-67
staining of tumor section from 0% MSC group. (E) Ki-67 staining of tumor section from 10% MSC group. (F) Quantification and comparison of Ki-67 staining
between 0% and 10% MSC groups. Ki-67 staining from 10% MSC group was higher than in 0% MSC group (61.8% vs. 44.0%). ***P=0.001, Student’s t test.
(G) Phospho-EGFR (p-EGFR) staining of tumor section from 0% MSC group. (H) p-EGFR staining of tumor section from 10% MSC group. (I) Quantification
and comparison of p-EGFR staining between 0% and 10% MSC groups. p-EGFR staining from 10% MSC group was higher than in 0% MSC group (69.5% vs.
49.4%). *P= 0.05, Student’s t test. Scale bar is 200 μm in all images.
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weight loss in the MSC vs. no MSC groups. Finally, bioi-
maging after tumor resection for the appearance of me-
tastases indicated that erlotinib inhibited the rapid
development of post-resection metastases promoted by
MSCs, as can be appreciated in the Kaplan-Meier plots
in Figure 4F (in the 10% MSC group, 12 tumors devel-
oped in the 17 mice not treated vs. 4 in 10 mice treated
with erlotinib, 30 day metastasis-free survival 47% in
mice co-injected with 10% MSC vs. 80% in 10% MSC
mice treated with erlotinib P <0.0001, log-rank test).
E-cadherin, p-EGFR and Ki-67 staining of specimens
of primary tumor and metastases obtained from mice
treated with erlotinib versus control were examined byimmunohistochemistry. Although we previously re-
ported that E-cadherin was downregulated by MSCs in
SUM149 cells in vitro, we found here that E-cadherin
was not downregulated in tumors co-injected with
MSCs compared with controls. However, E-cadherin
was significantly downregulated in erlotinib-treated
tumors (P = 0.001, Student’s t test; Figure 5A and B),
which is consistent with the so-called ‘E-cadherin para-
dox’ described in clinical IBC in which E-cadherin ex-
pression is maintained in IBC tumors and metastases
but its downregulation leads to tumor regression [21].
Ki-67 was significantly decreased by erlotinib in both
the 0% and 10% MSC groups compared with respective
groups on the control diet (P = 0.001, Student’s t test;
Figure 4 (See legend on next page.)
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Figure 4 Mesenchymal stem/stromal cells (MSCs) increase the sensitivity of metastatic inflammatory breast cancer (IBC) xenografts to erlotinib.
SUM149 cells (5 × 105) were injected bilaterally into the cleared mammary fat pad of SCID/Beige mice with or without MSCs (10% of total number of cells
injected per mammary gland, see Scheme 1). Mice were treated with erlotinib diet (dose of 40 mg/kg per day). Treatment started on day 1 following
injection of cells and ended 17 weeks later. Tumor growth was monitored and tumors were resected in a survival surgery when tumors reached a volume of
300 mm3. Development of metastases was monitored for 8 weeks post-resection of primary tumor. (A) Tumor growth curves of 0% MSC groups treated with
and without erlotinib, prepared with average of tumor burden per mouse. Green arrow indicates when erlotinib treatment was discontinued. (B) Tumor
growth curves of 10% MSC groups treated with and without erlotinib, prepared with average of tumor burden per mouse. Green arrow indicates when
erlotinib treatment was discontinued. (C) Tumor growth curves of 0% and 10% MSC groups treated with erlotinib, prepared with average of tumor burden
per mouse, showing no statistical difference between groups. P=NS, Student’s t test. Green arrow indicates when erlotinib treatment was discontinued. (D)
Tumor growth curves of 0% and 10% MSC groups treated with erlotinib, prepared with average of tumor volume per side of injection, showing no difference
between right side of 0% and 10% groups and left side of 0% and 10% groups. Green arrow indicates when erlotinib treatment was discontinued. (E) Tumor
growth curves between weeks 15 and 19 of 0% and 10% MSC groups treated with erlotinib, prepared with average of tumor volume per side of injection,
showing that erlotinib inhibited the effects promoted by MSC in the contralateral tumors. Erlotinib treatment was stopped at 17 weeks (green arrow). (F)
Metastasis-free survival curve. Purple line, 10% MSC group treated with erlotinib diet; tan line, 0% MSC group treated with erlotinib diet; blue line, 0% MSC
group treated with control diet; green line, 10% MSC groups treated with control diet. P= 0.001, log-rank test. Erlotinib treatment inhibited mice co-injected
with 10% MSC to developed spontaneous metastasis after resection in comparison with 10% MSC untreated group.
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nificantly decreased in the 10% MSC group after erloti-
nib treatment (P = 0.03, Student’s t test; Figure 5E and
F). More importantly, we observed that treatment with
erlotinib reduced Ki-67 staining and completely abol-
ished p-EGFR staining in the metastases of the 10%
MSC group (Figure 5G-J). These findings, in combin-
ation with the reduction in metastases, suggest that the
increased EGFR signaling promoted by MSC co-
injection made these cells more sensitive to erlotinib
treatment.
p-EGFR tumor and stromal staining intensity is correlated
in IBC but not in non-IBC patient samples
To examine the relationship between tumor and stroma in
human breast tumor tissues two tumor microarrays (45
IBC cases and 30 locally advanced non-IBC cases) were
stained for p-EGFR. Tissues were collected after neoadju-
vant chemotherapy in 61 cases and p-EGFR amplification
was not examined. Non-IBC patients included T1c-T4b
with 20 patients having T4 disease (19 patients had stage
III disease, 11 patients had stage IV disease), the median
number of positive lymph nodes was 6. There were no sig-
nificant differences between estrogen receptor (ER) status,
human epidermal growth factor receptor 2 (HER2)-neu
overexpression, and triple-negative receptor status between
the IBC and non-IBC cohorts (all P >0.05, chi-squared stat-
istic). In the full cohort, intensity of p-EGFR staining in the
tumor was higher in HER2-neu overexpressed tumors (P =
0.036, chi-squared statistic) however this association was
not demonstrated in the IBC or non-IBC subsets perhaps
owing to small numbers. No other significant associations
between p-EGFR tumor or stroma intensity and receptor
status were observed in either the full cohort or the IBC/
non-IBC subsets. Among IBC cases, 43 tissues were scor-
able for p-EGFR staining in the stroma and 40 for p-EGFR
in tumor cells (Table 1). There was no significant difference
in use of neoadjuvant chemotherapy prior to samplecollection between IBC and non-IBC for any scorable end
point (all P >0.05, chi-squared statistic). Among non-IBC
patients, 24 were scorable for stroma and 20 for tumor
(Table 2). All non-IBC cases were p-EGFR positive in tumor
and stroma. Nine IBC cases were p-EGFR negative in tumor
and one was p-EGFR negative in stroma. Staining intensity
between the stroma and tumor cells was strongly correlated
in IBC patients (P <0.0001; Mantel-Haenszel test) but not
correlated in non-IBC patients (P= 0.1844; Mantel-Haenszel
test, Figure 6) suggesting reciprocal cross-talk between
stroma and tumor signaling may be more evident in IBC. p-
EGFR staining was not prognostic for distant metastatic-free
survival in this mixed cohort of patients that includes meta-
static and non-metastatic patients and varied treatments in
each group making comparisons imbalanced.
Discussion
In this study, we modified the tumor microenvironment
of IBC in a preclinical model by adding human bone
marrow-derived MSCs and their secreted factors to hu-
man breast cancer cells. We report for the first time that
altering the microenvironment in this way induced the
clinical IBC phenotype, specifically in promoting tumor
skin invasion and dermolymphatic tumor emboli forma-
tion, the propensity for metastases, and the E-cadherin
paradox. To date, only the Mary-X IBC model, which is
not widely available, shares these features and no inducible
model or other specific role for the microenvironment has
been described. We modeled mixed effects in the setting
of multiple simultaneous tumors, and identified EGFR as
a clinical target activated by tumor stromal cells that limits
the growth of highly proliferating, metastatic, E-cadherin-
positive cells in this IBC xenograft model. In clinical IBC
tissues a clear correlation is demonstrated between p-
EGFR staining in stromal and tumor cells in IBC
highlighting the relevance of this cross-talk. Finally, we
demonstrated a complete disconnect between the invasive
process induced by MSCs and tumor-initiating cells, an
Figure 5 (See legend on next page.)
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Figure 5 Epidermal growth factor receptor (EGFR) signaling in mice co-injected with SUM149 cells and mesenchymal stem/stromal cells (MSCs)
is decreased by erlotinib treatment. SUM149 cells (5 × 105) were injected bilaterally into the cleared mammary fat pad of SCID/Beige mice with or
without MSCs (10% of total number of cells injected per mammary gland, see Scheme 1). Mice were treated with erlotinib diet (dose of 40 mg/kg per day).
Treatment started on day 1 following injection of cells and ended 17 weeks later. Tumors were resected in a survival surgery when tumors reached a volume
of 300 mm3, fixed in formalin, embedded in paraffin, cut, stained and scored by a pathologist specialized in inflammatory breast cancer (IBC). Metastases were
collected and processed as the tumors 8 weeks post-resection of primary tumors. (A) Quantification and comparison of E-cadherin staining between control
(untreated) and erlotinib-treated groups of mice that were injected only with SUM149 cells. E-cadherin staining of tumor sections from 0% MSC group treated
with erlotinib was lower than in untreated 0% MSC group (control diet) (72.0% vs. 10.1%). ***P= 0.001, Student’s t test. (B) Quantification and comparison of
E-cadherin staining between control (untreated) and erlotinib-treated groups of mice that were co-injected with SUM149 cells and MSCs. E-cadherin staining
of tumor sections from 10% MSC group treated with erlotinib was lower than in untreated 10% MSC group (control diet) (70.0% vs. 14.6%). ***P= 0.001,
Student’s t test. (C) Quantification and comparison of Ki-67 staining between control (untreated) and erlotinib-treated groups of mice that were injected only
with SUM149 cells. Ki-67 staining of tumor sections from 0% MSC group treated with erlotinib was lower than in untreated 0% MSC group (control diet)
(39.0% vs. 8.9%). ***P= 0.001, Student’s t test. (D) Quantification and comparison of Ki-67 staining between control (untreated) and erlotinib-treated groups of
mice that were co-injected with SUM149 cells and MSCs. Ki-67 staining of tumor sections from 10% MSC group treated with erlotinib was lower than in
untreated 10% MSC group (control diet) (61.8% vs. 15.2%). ***P= 0.001, Student’s t test. (E) Quantification and comparison of phospho-EGFR (p-EGFR) staining
between control (untreated) and erlotinib-treated groups of mice that were injected only with SUM149 cells. p-EGFR staining of tumor sections from 0% MSC
groups was similar regardless of treatment with erlotinib (49.4% vs. 53.6%). P=NS, Student’s t test. (F) Quantification and comparison of p-EGFR staining
between control (untreated) and erlotinib-treated groups of mice that were co-injected with SUM149 cells and MSCs. p-EGFR staining of tumor sections from
10% MSC group treated with erlotinib was lower than in untreated 10% MSC group (control diet) (69.3% vs. 44.0%). ***P= 0.03, Student’s t test. (G) Ki-67
staining of metastasis section from 10% MSC group in control diet. (H) Ki-67 staining of metastasis section from 10% MSC group in erlotinib diet. (I) p-EGFR
staining of metastasis section from 10% MSC group in control diet. (J) p-EGFR staining of metastasis section from 10% MSC group in erlotinib diet. Scale bar
is 100 μm in all images.
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this disease.
IBC accounts for up to 10% of all breast cancer mortality
because of treatment resistance and the propensity for early
metastasis. To date, no IBC-specific therapies exist, in part
because of the lack of models that faithfully recapitulate the
clinical features of the disease [22]. Five cell lines have been
described, KPL-4, SUM149, SUM190, MDA-IBC3, and
WIBC-9, that can be passaged and manipulated in standard
cell culture. Although skin invasion has been described in
xenografts from several of these cell lines, it is often not well
quantified, and dermal lymphatic invasion is not uniformlyTable 1 p-EGFR expression status in tumor and stroma of IBC
p-EGFR expression status in tumor: No. of patie
Negative Positive P
ER expression
Negative 5 (22.7) 17 (77.3) 0.279
Positive 4 (22.2) 14 (77.8)
PR expression
Negative 4 (17.4) 19 (82.6) 0.304
Positive 5 (29.4) 12 (70.6)
HER2 expression
Negative 8 (28.6) 20 (71.4) 0.226
Positive 0 (0.0) 8 (100.0)
Triple-negative status
No 5 (18.5) 22 (81.5) 0.484
Yes 3 (33.3) 6 (66.7)
p-EGFR, phospho-epidermal growth factor receptor; IBC, inflammatory breast cance
growth factor receptor 2.robust. Mice with KLP4 xenografts develop cachexia and
die within a short time after xenografting, and some mice
develop tumors but have no signs or symptoms of the dis-
ease. Mary-X can be passaged as spheroids or on feeder cells
and faithfully recapitulates the disease, but this model is not
widely available. WIBC-9 can only be passaged in mice,
making cell labeling and further genetic modification diffi-
cult. Enhanced clinical phenotype in a commercially avail-
able cell line-based xenograft is an important advance for
examining the biology of numerous components of this dis-
ease (metastases, lymphovascular invasion, treatment resist-
ance) that seem to be mediated by distinct biology, and it ispatient samples
nts (%) p-EGFR expression status in stroma: No. of patients (%)
Negative Positive P
1 (4.2) 23 (95.8) 0.810
0 (0.0) 19 (100.0)
1 (3.8) 25 (96.2) 0.778
0 (0.0) 17 (100.0)
1 (3.6) 27 (96.4) 0.337
0 (0.0) 10 (100.0)
0 (0.0) 29 (100.0) 0.329
1 (11.1) 8 (88.9)
r; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal
Table 2 p-EGFR expression status in tumor and stroma of non-IBC patient samples
p-EGFR expression status in tumor: No. of patients (%) p-EGFR expression status in stroma: No. of patients (%)
Negative Positive P Negative Positive P
ER expression
Negative 0 (0.0) 12 (100.0) 0.949 0 (0.0) 13 (100.0) 0.437
Positive 0 (0.0) 8 (100.0) 0 (0.0) 11 (100.0)
PR expression
Negative 0 (0.0) 13 (100.0) 0.546 0 (0.0) 15 (100.0) 0.565
Positive 0 (0.0) 7 (100.0) 0 (0.0) 9 (100.0)
HER2 expression
Negative 0 (0.0) 14 (100.0) 0.598 0 (0.0) 15 (100.0) 0.285
Positive 0 (0.0) 4 (100.0) 0 (0.0) 7 (100.0)
Triple-negative status
No 0 (0.0) 15 (100.0) 0.787 0 (0.0) 19 (100.0) 0.410
Yes 0 (0.0) 3 (100.0) 0 (0.0) 3 (100.0)
p-EGFR, phospho-epidermal growth factor receptor; IBC, inflammatory breast cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal
growth factor receptor 2.
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environment can actually mediate the presentation and pro-
gression of this disease.
MSCs have been associated with tumor growth and
metastatic potential of breast cancer cells via activating
EMT in cancer cells [7,23], increasing tumor-initiating cell
populations [24], increasing vascular endothelial factor
(VEGF) signaling [25,26], and inducing the secretion of
the chemokine CCL5 [6]. We previously reported that ex-
posure to MSCs (direct contact) and MSC-CM (indirect
contact) increased the formation of primary mammo-
spheres and downregulated E-cadherin in IBC cell lines
including SUM149 [7], which suggests that the presence
of MSCs in the tumor microenvironment promoted EMT
and cancer stem cell surrogates in vitro. However, in-
creased EMT features induced by MSC-CM was not asso-
ciated with increased secondary mammosphere formation,
which is considered a more rigorous test of self-renewalFigure 6 Phospho-epidermal growth factor receptor (p-EGFR) tumor and
(IBC) but not in non-IBC. Primary tumor samples obtained from breast cancer
described in reference [18]) were used to create a tissue microarray (TMA), whic
pathologist specialized in IBC. (A) Representative p-EGFR staining of tumor secti
human epidermal growth factor receptor 2 (HER2) negative) scored as tumor 3+
non-IBC patient (ER/PR negative and HER2 positive) scored as tumor 2+ and strin vitro [7], and here, pretreating SUM149 cells with
MSC-CM decreased the tumor-initiation ability of cancer
cells in vivo.
Xiao et al. previously reported increased expression of
stem cell-related genes in the lymphovascular emboli of
Mary-X [27], and Charafe-Jauffret et al. demonstrated
that the tumor-initiating and metastasis-initiating cap-
acity of the SUM149 and Mary-X models lies in the
stem-like aldefluor-positive population and that the
presence of such cells is a marker of prognosis in pa-
tients with IBC. However, induction of skin invasion
from aldefluor-positive SUM149 cells was not described
[28]. Here we show that mediation of metastasis and
skin invasion by MSCs is independent of tumor-
initiating capacity in SUM149 cells and that co-injection
of MSCs had no effect on ALDH staining in primary tu-
mors. Although Liu et al. report increased cancer stem
cell activity from SUM149 cells and aldefluor-positivestromal staining intensity is correlated in inflammatory breast cancer
patients at MD Anderson Cancer Center (details about the patients are
h was stained for p-EGFR. Tumor and stroma staining was scored by a
on from IBC patient (estrogen receptor (ER)/progesterone receptor (PR) and
and stroma 3+. (B) Representative p-EGFR staining of tumor section from
oma 0 to 1. 400X magnification in both images.
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in vitro (data not shown) and used unsorted MSCs cul-
tured in mammosphere protocols as described previ-
ously [7]. Karnoub et al. previously demonstrated that
MSCs enhance metastases by promoting homing to the
premetastatic niche [6], and we speculate that, contrary
to our hypothesis, MSCs induce homing locally and dis-
tantly as opposed to increasing tumor-initiating capacity.
As noted above, although E-cadherin expression is clas-
sically associated with less aggressive epithelial cells, E-
cadherin is overexpressed in IBC primary tumors and
metastases. Notably, the World IBC Consortium reported
an IBC-specific attenuation of tumor growth factor-beta
(TGFβ) signaling and TCF4/TCF4 transcription factor ac-
tivity, both of which are involved in the induction of EMT
[3], and Chu et al. showed that reduced expression of E-
cadherin promotes substantial reduction of the in vivo
growth capability of primary tumors and metastasis in the
SUM149 and MARY-X IBC models [21]. Although in the
current study, in vitro co-culture of MSCs or MSC-CM
with SUM149 cells led to reduced E-cadherin expression,
co-injection of the IBC cell line SUM149 with MSCs did
not decrease E-cadherin in primary SUM149 xenografts.
These findings highlight the similarity between the
SUM149-MSC model and clinical IBC in recapitulating the
E-cadherin paradox of IBC. This apparent disconnect be-
tween the in vitro and in vivo studies suggests that in IBC,
additional microenvironmental factors in vivo further mod-
ify the results. Prior in vitro and in vivo studies of E-
cadherin expression in the Her2-neu-positive xenograft
MDA-IBC3 were similarly disparate. MDA-IBC3 showed
very little in vitro attenuation by MSC or MSC-CM, but
demonstrated marked decrease in E-cadherin in primary
tumors co-injected with MSC [7]. These results may impli-
cate additional regulatory elements present in vivo that
regulate E-cadherin expression. Although no gross differ-
ences in macrophage numbers were seen in the co-injected
MSC versus control tumors, differences in polarization of
macrophages was not examined. T cells have been impli-
cated in the development of micrometastatic disease [29],
but this cannot be assessed in this immunocompromised
mouse model. Whether the E-cadherin results previously
reported in the MDA-IBC3 model are more typical of
Her2-amplified IBC or are simply a function of a less rele-
vant IBC model cannot be ascertained from the available
data. EMT-regulating factors have been linked to in-
creased mammosphere formation and tumor-initiating
cells [30], and loss of E-cadherin is a hallmark of EMT
that correlates with promotion of invasion and metastasis
[31], but because E-cadherin is overexpressed in this
highly metastatic disease and maintained with MSC pro-
motion of IBC features, our in vivo results validate the dis-
connect between the EMT-tumor-initiating cell axis and
metastasis in IBC.The influence of MSCs on tumor growth is still contro-
versial [5]. The results of our bilateral injection experi-
ment demonstrate that MSCs can promote simultaneous
changes in the tumor microenvironment and premeta-
static niche, which may account for some of the discrep-
ancies reported in the literature. In the current study,
tumors that contained MSCs grew at similar rates as con-
trol tumors; however, those same MSCs significantly de-
layed the growth of their respective contralateral tumors,
likely by indirect secretion of inhibitory factors, whereas
metastases and skin invasion were simultaneously pro-
moted in both sides. Interestingly, although mice with
MSCs had slower-growing tumors, Ki-67 staining of those
tumors was higher, no difference in staining for apoptosis
(caspase 3) was found, and this group of mice developed
more metastases within 8 weeks after primary tumor re-
section than the control group, which is consistent with
the ‘go or grow’ hypothesis. Together these results suggest
that MSCs can modify the tumor microenvironment, the
motility of cancer cells, and their ability to migrate to new
locations to spontaneously establish micrometastases.
EGFR-targeted therapy has had discouraging results in
breast cancer treatment studies that include all subtypes
of breast cancer [32-34]. However, a recent study in pa-
tients with triple-negative disease was encouraging [35].
In the past few years, new evidence has emerged that
EGFR is specifically important for IBC, as EGFR is over-
expressed and is a predictor of poor prognosis and worse
overall survival and risk of recurrence in this aggressive
form of breast cancer [9,10]. Zhang et al. demonstrated
that erlotinib is effective for the treatment of spontan-
eous lung metastases [11]. Our work here described
shows that erlotinib, a small molecule that targets EGFR,
can prevent or reduce MSC-promoted metastases after
primary tumor resection in an IBC preclinical model,
and as such this type of therapy may be best used in pa-
tients with MSC-stimulated tumors, as these tumors
may be more sensitive to this approach. In addition, we
confirmed here that p-EGFR staining intensity between
the stroma and tumor cells is strongly correlated in IBC
patients but not correlated in non-IBC patients. Earlier,
Nieto et al. [36] reported that detection of p-EGFR was
not associated with outcome. We observed that p-EGFR
staining was not prognostic for distant metastatic-free
survival.
A limitation of this study was the toxic effects caused
by the dosage of erlotinib on the preclinical model used
in our study. Nevertheless, the clinical results in triple-
negative breast cancer combined with the now signifi-
cant body of preclinical data regarding the role of EGFR
in IBC strongly suggest EGFR targeting should not be
abandoned for IBC based on studies in non-IBC. In-
deed, very recently, it was reported that an IBC patient
with amplified Her2/neu and mutated EGFR (L858R)
Lacerda et al. Breast Cancer Research  (2015) 17:42 Page 16 of 17responded to EGFR-targeted therapy using erlotinib
(150 mg/day) for eight months [37]. A clinical study in
which the EGFR inhibitor panitumumab is added to sys-
temic chemotherapy in the neoadjuvant setting for IBC
is currently accruing.
The lack of robust markers for MSCs that can be used for
immunohistochemical analysis is a significant limitation in
identifying patients with MSC-promoted tumors at this
time, but is a critical need. Newer multiplexed imaging plat-
forms may permit further clinical characterization of MSC
in IBC tissues [38]. In addition, genomic profiling (clinical
next-generation sequencing) might allow stratifying IBC pa-
tients and offer a personalized therapeutic option to the
ones with EGFR mutations [37]. New therapeutic agents are
urgently needed for IBC, specifically those that are targeted
to the distinct characteristics of this type of breast cancer.
Conclusions
We demonstrated here that IBC symptoms can be induced
by the microenvironment; therefore, this works paves the
way for future studies examining therapies that target the
microenvironmental changes that affect IBC. Further, we
validated the unusual biology of IBC that seems to be inde-
pendent of the EMT-tumor-initiating cell axis, although an
independent role for tumor-initiating cells is supported by
the existing literature. A growing body of preclinical litera-
ture now supports a role for EGFR signaling in mediating
IBC progression. Our findings add to this knowledge and
implicate MSCs and EGFR in establishing metastases after
surgery, suggesting a role for EGFR blockade in preventing
metastases.
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Additional file 1: Figure S1. PI and Annexin V staining of SUM149 cells
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Additional file 2: Figure S2. Quantification of GFP- and Tomato
red-labeled tumor cells in each collected tumor. Image of lung metastasis
showing GFP- and Tomato red-labeled tumor cells.
Additional file 3: Figure S3. Quantification of caspase 3, ALDH and F4/
80 staining of tumor sections from 0% and 10% MSC groups.
Additional file 4: Figure S4. Average weight of mice during the course
of the experiment and H&E staining of tumor sections from mice treated
with erlotinib diet.
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